Oral vs injectable GLP-1: bioavailability and efficacy comparison — what worked for you?

TinaHashiRN said:

I went looking for why the dosing schedule is what it is and found that almost every practical question on this board has a pharmacokinetic answer…

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing. Semaglutide:

• Tmax: 24-72 hours post-injection
• T½: ~168 hours (7 days) — enables weekly dosing
• Steady state: reached at 4-5 weeks
• Bioavailability (SubQ): ~89%
• Volume of distribution: ~12.5L (primarily plasma)

The albumin binding (>99%) is the key pharmacological innovation — creating a sustained-release effect from a single injection. Previous GLP-1 agonists (exenatide) required BID dosing due to rapid clearance.

Dr.GastroMayo said:

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing.

No disagreement with Dr.GastroMayo. One condition attached. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

TinaHashiRN said:

I went looking for why the dosing schedule is what it is and found that almost every practical question on this board has a pharmacokinetic answer…

Same pattern here, and in the same order.

Clinical perspective, offered as context rather than as advice.

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].

Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.

Early-stage data — interpret with caution. But the trajectory is extraordinary.